Get the Stockscreener App
25.35
3.58%
-0.94
Pre-market:
25.20
-0.15
-0.59%
Summit Therapeutics Inc stock is traded at $25.35, with a volume of 2.40M.
It is down -3.58% in the last 24 hours and down -3.24% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$26.29
Open:
$25.63
24h Volume:
2.40M
Relative Volume:
0.65
Market Cap:
$18.83B
Revenue:
$956.00K
Net Income/Loss:
$-221.32M
P/E Ratio:
-79.22
EPS:
-0.32
Net Cash Flow:
$-142.25M
1W Performance:
-1.30%
1M Performance:
-3.24%
6M Performance:
+17.36%
1Y Performance:
+106.94%
1-Day Range:
$25.04
$25.83
1-Week Range:
$25.04
$27.84
52-Week Range:
$11.76
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
25.35 | 19.83B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit stock gets Neutral view at Piper Sandler (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism - MSN
Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target - MarketScreener
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call - MSN
Top 3 Growth Stocks to Buy in August: Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals - AInvest
3 Fantastic Growth Stocks to Buy in August - The Globe and Mail
Does Summit Therapeutics Inc. show high probability of rebound2025 Top Gainers & Community Verified Swing Trade Signals - Newser
What is the dividend yield of Summit Therapeutics Inc.2025 Earnings Surprises & Reliable Breakout Stock Forecasts - thegnnews.com
Is it too late to sell Summit Therapeutics Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
Cantor Fitzgerald Has Weak Outlook for SMMT FY2025 Earnings - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns “Buy” Rating from HC Wainwright - Defense World
Summit Therapeutics Inc.’s Beta Climbs After Market VolatilityMarket Sentiment Report & Consistent Profit Trade Alerts - metal.it
Summit Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - Newser
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
What makes Summit Therapeutics Inc. stock price move sharplySwing Trade & Smart Investment Allocation Insights - thegnnews.com
How to build a dashboard for Summit Therapeutics Inc. stock2025 Market WrapUp & Expert-Curated Trade Recommendations - Newser
11 Best Short Squeeze Stocks to Buy Now - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Downgraded to Sell Rating by Wall Street Zen - Defense World
Pattern recognition hints at Summit Therapeutics Inc. upsidePortfolio Gains Report & Proven Capital Preservation Methods - Newser
SVP, US Marketing at Summit Therapeutics Inc. Job - Mediabistro
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday - MSN
Strategies to average down on Summit Therapeutics Inc.July 2025 Fed Impact & Real-Time Market Trend Scan - Newser
Summit Therapeutics Faces Questions Over Its Cash Burn And Future - Finimize
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 - Stock Titan
Custom Dashboard Highlights Summit Therapeutics Inc. Price MomentumJuly 2025 Technicals & Reliable Intraday Trade Plans - beatles.ru
Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says - 富途牛牛
Why Summit Therapeutics Shares Are Poised for Growth - TipRanks
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $33 to $35 - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Glaukos (GKOS) - The Globe and Mail
Evercore ISI Issues Positive Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock Price - Defense World
Summit Therapeutics shares rise 2.16% premarket after earnings results reported. - AInvest
10 Stocks That Vanished in Value - Insider Monkey
Summit Therapeutics’ Promising Advancements in Cancer Treatment Drive Buy Rating - TipRanks
SMMT Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Positive Outlook for Summit Therapeutics: Buy Rating Supported by Financial Stability and Strategic Developments - TipRanks
Summit Therapeutics notes ‘doubt’ about ability to continue as ‘going concern’ - TipRanks
Summit Therapeutics Plummets 11.9% Amid Legal Storm: What’s Brewing in Biotech? - AInvest
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus - Nasdaq
Summit Therapeutics price target raised to $33 from $30 at Clear Street - TipRanks
Evercore ISI Group Raises Summit Therapeutics PT to $34, Maintains Outperform Rating - AInvest
Summit Therapeutics stock price target raised to $34 by Evercore ISI - Investing.com Canada
Summit Therapeutics shares fall 3.72% premarket after reporting Q2 financial results and operational updates. - AInvest
Summit Therapeutics Inc. Securities Fraud LawsuitClass Action Opportunity - AInvest
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Summit Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Summit Therapeutics Q2 Loss Widens to $0.12 per Share - AInvest
Summit Therapeutics Q2 Adjusted Loss Widens - MarketScreener
Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - Placera.se
Summit Therapeutics Amends Stock Distribution Agreement - TipRanks
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.12 per Share, vs. FactSet Est of $-0.10 - MarketScreener
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.64%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):